Patients who have received prior anti-PD directed therapy (monoclonal antibody [mAb] or small molecule) are not eligible
Antibodies: >=  days must have elapsed from infusion of last dose of antibody, and toxicity related to prior antibody therapy must be recovered to grade =< 
>=  days must have elapsed from infusion of lase dose of antibody, and toxicity related to prior antibody therapy must be recovered to grade =< 
Antibodies: >=  days must have elapsed from infusion of last dose of antibody, and toxicity related to prior antibody therapy must be recovered to grade =< 
Treatment with a monoclonal antibody within  days prior to Cycle , Day 
Prior use of any monoclonal antibody, radioimmunoconjugate, or antibody-drug conjugate within  weeks before first infusion
Immune therapy (including monoclonal antibody therapy) - weeks
>=  days must have elapsed from infusion of last dose of antibody, and toxicity related to prior antibody therapy must be recovered to grade =< 
At least  weeks must have elapsed since prior therapy that includes a monoclonal antibody prior to registration
Prior treatment with an antiPD, antiPDL, antiPDL, antiCD, or antiCTLA antibody, or any other antibody or drug specifically targeting Tcell co-stimulation or checkpoint pathways.
Antibodies: >=  days must have elapsed from infusion of last dose of antibody, and toxicity related to prior antibody therapy must be recovered to grade =< 
Patients who have had prior monoclonal antibody therapy must have completed that therapy >=  weeks (or  half-lives of the antibody, whichever is shorter) prior to enrollment on protocol (minimum of  week between prior therapy and study enrollment)
Monoclonal antibody or antibody-drug conjugate (ADC) therapy within  weeks prior to Day  of Cycle .
Prior treatment against NSCLC with an EGFR monoclonal antibody
> =  days must have elapsed from infusion of last dose of antibody and toxicity related to prior antibody therapy must have recovered to Grade <= .
? days for prior monoclonal antibody used for anticancer therapy with the exception of denosumab.
Monoclonal antibodies: At least  days or  half-lives, whichever is longer, must have elapsed since prior treatment with a monoclonal antibody.
Prior treatment with a monoclonal antibody or chimeric antigen receptor T cell infusion for the treatment of AML
No monoclonal antibody within  months unless evidence of disease progression
Prior chemotherapy: Patients should be at least  days from last chemotherapy dose prior to start of CED infusion, with exception of antibody half-lives. For antibody therapies, at least  half-lives of the antibody after last dose of monoclonal antibody should have passed prior to CED infusion
At least  half-lives must have elapsed since prior therapy that included a monoclonal antibody with the exception of blinatumomab; patients must have been off blinatumomab infusion for at least  days and all drug related toxicity must have resolved to grade  or lower as outlined in the inclusion/exclusion criteria
Prior monoclonal antibody therapy within  half-lives or  days prior to apheresis, whichever is greater
Four weeks must have elapsed since any prior antibody therapies to allow antibody levels to decline
Antibody therapy
Monoclonal antibody treatment: at least three half-lives must have elapsed prior to registration
Patients must not have had chemotherapy, major surgery, monoclonal antibody therapy or experimental therapy within the  days prior to the start of ibrutinib administration
Received a monoclonal antibody or immunoglobulin -based agent within  year of Screening, or has documented immunogenicity to a prior biologic.
Had a prior anti-cancer monoclonal antibody (other than pembrolizumab) within  days prior to start of study treatment, or failure to recover to CTCAE Grade  or better from the adverse events of prior therapies
Must not have received monoclonal antibodies within at least  half-lives of the antibody after its last dose.
Patients who have received any monoclonal antibody therapy within  weeks prior to entering the study
Patients who have received monoclonal anti-cancer antibody within  weeks of first dose of study drugs
Patients should be at least  days from last chemotherapy dose prior to start of CED infusion, with exception of antibody half-lives; for antibody therapies, at least  half-lives of the antibody after last dose of monoclonal antibody should have passed prior to CED infusion
Prior chemotherapy, immunotherapy, radioactive, or biological cancer therapy (including monoclonal antibody [mAb]) within  days prior to registration
Prior use of any monoclonal antibody within  months of the start of Cycle 
Monoclonal antibody within  half-lives of the antibody prior to initiating protocol therapy
Patients who have had prior exposure to immune checkpoint inhibitors are not eligible; please contact principal investigator, William Gradishar at -- for specific questions on potential interactions\r\n* PD- monoclonal antibody: pembrolizumab, pidilizumab, MEDI-, anti-PD- fusion protein AMP- (AMP-), anti-PD- checkpoint inhibitor PF- (PF-), anti-PD- monoclonal antibody BGB-A (BGB-A), anti-PD- monoclonal antibody PDR (PDR), anti-PD- monoclonal antibody REGN (REGN), anti-PD- monoclonal antibody SHR- (SHR-)\r\n* PD-L monoclonal antibody: durvalumab, avelumab, anti-PD-L monoclonal antibody MDX- (MDX-), atezolizumab, zirconium Zr -labeled anti-PD-L monoclonal antibody MPDLA (MPDLA)\r\n* CTLA monoclonal antibody: tremelimumab, abatacept\r\n* OX: agonistic anti-OX monoclonal antibody MEDI (MEDI), agonistic anti-OX monoclonal antibody MEDI (MEDI), anti-OX monoclonal antibody MEDI (MEDI), oxelumab, anti-OX antibody PF- (PF-)
Any of the following within  weeks prior to initiating study treatment\r\n* Systemic biologic therapy\r\n* Monoclonal antibody\r\n* Chemotherapy\r\n* TSEB \r\n* Phototherapy\r\n* Other investigational therapy
Patients who have received a prior monoclonal antibody =<  days prior to study day - are not eligible
At least three () half-lives of the antibody must have elapsed since the last dose of a monoclonal antibody
Eight weeks must have elapsed from the time of any antibody therapy that could affect an anti-cancer immune response, including anti-cytotoxic T-lymphocyte-associated protein  (CTLA ) therapy, at the time the patient receives the preparative regimen to allow antibody levels to decline; Note: patients who have previously received ipilimumab and have documented gastrointestinal (GI) toxicity must have a normal colonoscopy with normal colonic biopsies
At least  half-lives must have elapsed since prior therapy that included a monoclonal antibody
Four weeks must have elapsed from the time of any antibody therapy that could affect an anti-cancer immune response at the time the patient receives the preparative regimen to allow antibody levels to decline
Prior systemic use of any immunosuppressive chemotherapy (except low dose methotrexate) and/or monoclonal antibody treatment for CTCL
Monoclonal antibody(ies) (At least  half-lives since the last dose of any monoclonal antibody prior to first dose of tazemetostat)
Known allergic reaction to a prior monoclonal antibody therapy or have any documented Anti-Drug Antibody (ADA) response
Prior therapy with monoclonal antibody (mAb) against CTLA-
At least  days must have elapsed after the last of a biologic agent that is not a monoclonal antibody, to be enrolled on this study
At least  half-lives must have elapsed after treatment with a monoclonal antibody and enrollment on this study
At least  half-lives of the antibody after the last dose of a monoclonal antibody.
Monoclonal antibodies: at least  half-lives of the antibody after the last dose of a monoclonal antibody; specifically for bevacizumab  days after the last dose
Presence of antibody against basiliximab in serum (only required for patients who have received prior antibody)
Patients must be at least  days post cytotoxic chemotherapy, and/or monoclonal antibody therapy (excluding bone-directed therapy), prior to enrollment
Monoclonal antibodies: At least  days or  half-lives, whichever is longer, must have elapsed since prior treatment with a monoclonal antibody.
At least  half-lives should have elapsed since therapy with a monoclonal antibody
Use of other anticancer treatments or agents within the past  weeks ( weeks if the therapy was a monoclonal antibody)
Presence of antibody against basiliximab (only required for patients who have received prior antibody)
Antibodies:  half-lives must have elapsed from infusion of last dose of antibody (including checkpoint inhibitors), and toxicity related to prior antibody therapy must be recovered to Grade ?.
Received any antibody targeting T-cell check point or co-stimulation pathways within  weeks, received any other monoclonal antibody within  weeks, and all other immunotherapy (tumor vaccine, cytokine, or growth factor) within  weeks prior to study treatment.
Prior treatment with a HER antibody
Prior treatment with a monoclonal antibody within  days of receiving the first dose of study drugs.
Monoclonal antibody within  days prior to day  of protocol therapy
Any of the following:\r\n* Prior anti-cancer monoclonal antibody (mAb) =<  weeks prior to registration
Monoclonal antibodies: at least  half-lives of the antibody after the last dose of a monoclonal antibody
Monoclonal antibody therapy administered within  days of the agent prior to apheresis
Monoclonal antibody (ies) (At least  half-lives since the last dose of any monoclonal antibody prior to first dose of tazemetostat)
Has received prior treatment with a monoclonal antibody within  half-lives of Study Day 
At least  weeks from end of monoclonal antibody therapy
Received prior treatment (for any reason)with a monoclonal antibody within  half-lives of initiating study treatment
Prior monoclonal antibody treatment within  weeks before study Day 
Monoclonal antibody (ies) At least  days
Has received prior treatment with a monoclonal antibody within  half-lives of Study Day 
Prior use of any monoclonal antibody, radio-immuno-conjugate or antibody drug conjugate within  weeks before study start
Monoclonal antibody; at least three half-lives since the last dose
Monoclonal antibody therapy within  weeks prior to the planned start of study treatment.
Prior use of any monoclonal antibody or antibody-drug conjugate within  weeks before Cycle , Day 
Received prior monoclonal antibody (mAb) within  weeks prior to study.
Subjects who have previously received anti-GD monoclonal antibodies for biologic therapy or for tumor imaging are eligible unless they have had progressive disease while receiving prior anti-GD therapy; subjects who have received autologous marrow infusions or autologous stem cell infusions that were purged using monoclonal antibody linked to beads, but no other form of anti-GD monoclonal antibody, are eligible
Monoclonal antibody, radioimmunoconjugate, antibody-drug conjugate, chemotherapy, or other investigational anti-cancer agent within  weeks prior to study drug
The participant has undergone major surgery or received anti-cancer monoclonal antibody therapy in the -days prior to study enrollment.
Has had a prior monoclonal antibody therapy within  weeks prior to study Day . (Prior anti-HER therapy is acceptable).
Patient has a known hypersensitivity to cetuximab or any other monoclonal antibody
Patient has had a prior monoclonal antibody for treatment of MCC
Received an anti-CLL monoclonal antibody within  weeks prior to the first dose of study drug
Subjects must have completed at least  half-life periods from the last dose of monoclonal antibody prior to registration \r\n* Note: a list of half-lives of commonly used monoclonal antibodies is available on the Pediatric Brain Tumor Consortium (PBTC) website under Generic Forms and Templates
At least  antibody half?lives must have elapsed since the last dose of monoclonal antibody (e.g.,  days for rituximab and  days for epratuzumab) before subjects may initiate study treatment.
Monoclonal antibodies: ? days or  half-lives (whichever is shorter) of the antibody must have elapsed after the last dose of a monoclonal antibody (including checkpoint inhibitors). Toxicity related to prior antibody therapy must be recovered to Grade ?
Antibody therapy within  weeks prior to signing consent
Prior treatment with murine F is allowed; patients with prior mF, huF, monoclonal antibody ch. (ch.) or hu. monoclonal antibody (hu.) treatment must have human anti-huF antibody (HAHA) titer =<  enzyme-linked immunosorbent assay (ELISA) units/ml
A -week washout period is required from previous treatments (with the exception of a -week washout for antibody-directed or immunoglobulin-based immune therapy, or other monoclonal antibody therapies), unless it is not in the best interest of the patient in the opinion of the investigator. Individual cases should be discussed with the project clinician before enrollment.
Corticosteroid therapy within  weeks or immunosuppressive chemotherapy or any antibody-directed or immunoglobulin-based immune therapy (e.g., immunoglobulin replacement, other monoclonal antibody therapies) within  weeks of first dose of study drug
monoclonal antibody therapy must be completed at least  weeks prior to pre-infusion lymphodepletive chemotherapy
Six weeks must have elapsed since any prior antibody therapy including anti-cytotoxic T-lymphocyte-associated protein  (CTLA) antibody therapy that could affect any anti-cancer immune response, at the time the patient receives the preparative regimen to allow antibody levels to decline; (NOTE: patients who have previously received ipililumab and have documented gastrointestinal [GI] toxicity must have a colonoscopy with normal colonic biopsies)
Prior cetuximab, panitumumab, or other monoclonal antibody therapy allowed if given  days prior to the st infusion of armed T cells
At least  half-lives of the antibody must have elapsed after the last dose of monoclonal antibody. (i.e. gemtuzumab =  days)
Previously received an EGFR-directed monoclonal antibody within the past  weeks.
Monoclonal antibodies: At least  half-lives of the antibody must have elapsed after the last dose of monoclonal antibody. (ie. Rituximab= days, Epratuzumab= days)
Subject has received a monoclonal antibody for anticancer intent within  weeks prior to the first dose of study drug.
Monoclonal antibody therapy <  days from study enrollment
Six weeks must have elapsed from the time of any antibody therapy that could affect an anti-cancer immune response, including anti-cytotoxic T-lymphocyte-associated protein  (CTLA) antibody therapy at the time the patient receives the preparative regimen to allow antibody levels to decline; note: patients who have previously received ipilimumab and have documented gastrointestinal (GI) toxicity must have a normal colonoscopy with normal colonic biopsies
Six weeks must have elapsed from the time of any antibody therapy that could affect an anti cancer immune response, including anti-cytotoxic T-lymphocyte-associated protein (CTLA) antibody therapy, at the time the patient receives the preparative regimen to allow antibody levels to decline \r\n* Note: patients who have previously received ipilimumab and have documented gastrointestinal (GI) toxicity must have a normal colonoscopy with normal colonic biopsies
Monoclonal antibody therapy less than  month
Monoclonal antibodies: at least  weeks must have elapsed since prior therapy that included a monoclonal antibody
Treatment with chemotherapy or monoclonal antibody within  days prior to entering the study
Treatment with chemotherapy or monoclonal antibody during the time of participation in this trial
Prior treatment with any investigational drug, chemotherapy, or monoclonal antibody within the preceding  month
Less than four weeks since last monoclonal antibody-containing therapy
Known hypersensitivity to afatinib, monoclonal antibody
Six weeks must have elapsed from the time of any antibody therapy that could affect an anti cancer immune response, including anti-cytotoxic T-lymphocyte antigen  (CTLA) antibody therapy at the time the patient receives the preparative regimen to allow antibody levels to decline; Note: patients who have previously received ipilimumab and have documented gastrointestinal (GI) toxicity must have a normal colonoscopy with normal colonic biopsies
Patients who have not yet completed at least  days ( days for prior monoclonal antibody therapy) since receiving other investigational drugs
Therapeutic monoclonal antibody use within the longer of  weeks or  plasma half-lives
Donor must be HIV-& antibody and HTLV-& antibody sero-negative by FDA licensed test.
Recipient must be HIV-& antibody and HTLV-& antibody sero-negative by FDA licensed test.
For patients who have received prior anti-cytotoxic T-lymphocyte antigen (CTLA) monoclonal antibody therapy (ipilimumab or tremelimumab), there is a risk of bowel perforation with IL- therapy; therefore, for these patients if they have a history of colitis or diarrhea during anti-CTLA monoclonal antibody therapy, they should have a formal evaluation by a gastroenterologist and a colonoscopy should be considered to demonstrate the absence of active bowel inflammation before initiating IL- therapy on this protocol
Prior monoclonal antibody: participants having received prior in vivo monoclonal anti-GD antibodies for biologic therapy or for tumor imaging AND experienced a severe allergic reaction while receiving prior anti-GD therapy; (Note: participants who have received previous therapy with anti-GD monoclonal antibodies are eligible for this study, provided they did not experience a severe allergic reaction with the antibody)
Prior therapy with at least one first line standard therapy including check point inhibitors such as pembrolizumab, nivolumab, or ipilimumab\r\n* Note: six weeks must have elapsed from the time of any of these prior antibody therapies that could affect an anti-cancer immune response, at the time the patient receives the preparative regimen to allow antibody levels to decline\r\n* Note: patients who have previously received ipilimumab and have documented gastrointestinal (GI) toxicity must have a normal colonoscopy with normal colonic biopsies
Six weeks must have elapsed from the time of any antibody therapy that could affect an anti cancer immune response, including anti-cytotoxic T-lymphocyte-associated protein  (CTLA) antibody therapy, at the time the patient receives the preparative regimen to allow antibody levels to decline\r\n* Note: patients who have previously received ipilimumab and have documented GI toxicity must have a colonoscopy with normal colonic biopsies
ANTIBODY PROPHYLAXIS:
At least  days must have elapsed since the completion of therapy with a monoclonal antibody
Monoclonal antibody immunotherapies (eg, PD-, CTLA-):  weeks
Prior treatment with anti-GD monoclonal antibody is permitted only if human anti-human antibody titer is =<  assay developed by Dr. Nai-Kong Cheung
Monoclonal antibody: ? half-lives of antibody since last admin.
Known intolerance to CD monoclonal antibody therapy
